These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 11022216)

  • 1. Platelets and coronary intervention: some practical precautions.
    Blankenship JC; Iliadis EA
    J Invasive Cardiol; 2000 Oct; 12(10):536-8. PubMed ID: 11022216
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
    Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
    Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
    Kabbani SS; Aggarwal A; Terrien EF; DiBattiste PM; Sobel BE; Schneider DJ
    Am J Cardiol; 2002 Mar; 89(5):647-50. PubMed ID: 11867064
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
    Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
    Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
    Ramanathan A; Kleiman NS
    Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical use of glycoprotein IIb/IIIa inhibitors].
    Simonetti I; Gallopin M; Gensini GF
    Ann Ital Med Int; 1998; 13(3):163-8. PubMed ID: 9859573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
    Med Lett Drugs Ther; 1998 Sep; 40(1035):89-90. PubMed ID: 9760948
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in antiplatelet therapy for acute coronary syndromes.
    Clem JR; Falls S
    S D J Med; 1998 Jul; 51(7):233-4. PubMed ID: 9676157
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA; Ganti AK; Levitt R; Potti A
    Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In search of a superaspirin for the heart.
    Verheugt FW
    Lancet; 1997 May; 349(9063):1409-10. PubMed ID: 9164311
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute profound thrombocytopenia after c7E3 Fab therapy.
    Ferrari E; Thiry M; Touati C; Gibelin P; Baudouy M
    Circulation; 1997 Nov; 96(10):3809-10. PubMed ID: 9396511
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F; Oza R; Mascarenhas DA
    J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V; Mascarenhas D
    J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
    [No Abstract]   [Full Text] [Related]  

  • 17. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.
    Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH;
    J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451
    [No Abstract]   [Full Text] [Related]  

  • 18. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract]   [Full Text] [Related]  

  • 19. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier.
    Desai M; Lucore CL
    J Invasive Cardiol; 2000 Feb; 12(2):109-12. PubMed ID: 10731275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitors of GPIIb/IIIa platelet receptors].
    Chanu B
    Arch Mal Coeur Vaiss; 1999 Jul; 92(7):893-902. PubMed ID: 10443310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.